ATE553750T1 - Feste orale mikropartikelförmige darreichungsform zum schutz vor missbrauch - Google Patents

Feste orale mikropartikelförmige darreichungsform zum schutz vor missbrauch

Info

Publication number
ATE553750T1
ATE553750T1 AT05819412T AT05819412T ATE553750T1 AT E553750 T1 ATE553750 T1 AT E553750T1 AT 05819412 T AT05819412 T AT 05819412T AT 05819412 T AT05819412 T AT 05819412T AT E553750 T1 ATE553750 T1 AT E553750T1
Authority
AT
Austria
Prior art keywords
solid
active pharmaceutical
solid oral
pharmaceutical ingredient
protection against
Prior art date
Application number
AT05819412T
Other languages
English (en)
Inventor
Gerard Soula
Florence Guimberteau
Original Assignee
Flamel Tech Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flamel Tech Sa filed Critical Flamel Tech Sa
Application granted granted Critical
Publication of ATE553750T1 publication Critical patent/ATE553750T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT05819412T 2004-11-24 2005-11-21 Feste orale mikropartikelförmige darreichungsform zum schutz vor missbrauch ATE553750T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0452744A FR2878158B1 (fr) 2004-11-24 2004-11-24 Forme pharmaceutique orale, microparticulaire solide concue pour eviter le mesusage
PCT/FR2005/050973 WO2006056713A1 (fr) 2004-11-24 2005-11-21 Forme pharmaceutique orale microparticulaire solide concue pour eviter le mesusage

Publications (1)

Publication Number Publication Date
ATE553750T1 true ATE553750T1 (de) 2012-05-15

Family

ID=34952717

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05819412T ATE553750T1 (de) 2004-11-24 2005-11-21 Feste orale mikropartikelförmige darreichungsform zum schutz vor missbrauch

Country Status (8)

Country Link
US (1) US20080260844A1 (de)
EP (1) EP1814524B1 (de)
JP (1) JP2008520635A (de)
CN (1) CN101094653A (de)
AT (1) ATE553750T1 (de)
CA (1) CA2589169A1 (de)
FR (1) FR2878158B1 (de)
WO (1) WO2006056713A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
JP4732696B2 (ja) 2002-04-09 2011-07-27 フラメル・テクノロジー 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
FR2881652B1 (fr) * 2005-02-08 2007-05-25 Flamel Technologies Sa Forme pharmaceutique orale microparticulaire anti-mesuage
WO2006133733A1 (en) 2005-06-13 2006-12-21 Flamel Technologies Oral dosage form comprising an antimisuse system
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
FR2892937B1 (fr) * 2005-11-10 2013-04-05 Flamel Tech Sa Forme pharmaceutique orale microparticulaire anti-mesusage
HUE027537T2 (en) * 2007-09-03 2016-10-28 Nanotherapeutics Inc Granular preparations for the administration of poorly soluble drugs
EP2216015A4 (de) * 2007-11-02 2012-12-19 So Pharmaceutical Corp Komplex aus einem stoff mit geringer löslichkeit und einem tensid sowie verfahren zu seiner herstellung
EP2219612A4 (de) 2007-12-17 2013-10-30 Paladin Labs Inc Formulierung mit gesteuerter freisetzung und missbrauchsschutz
US8486449B2 (en) 2008-12-16 2013-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
US9730885B2 (en) 2012-07-12 2017-08-15 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2530563C2 (de) * 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen Analgetische Arzneimittel mit vermindertem Mißbrauchspotential
EP0198769A3 (de) * 1985-04-12 1987-09-02 Forest Laboratories, Inc. Schwimmfähige therapeutische Mittel mit verzögerter Freisetzung
EP0477135A1 (de) * 1990-09-07 1992-03-25 Warner-Lambert Company Kaubare kugelige überzogene Mikrokapseln und Verfahren zu ihrer Herstellung
GB9401894D0 (en) * 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
US6444246B1 (en) * 1997-12-16 2002-09-03 Mccormick & Company, Inc. Cake-resistant, hygroscopically sensitive materials and process for producing the same
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
BR0112124B1 (pt) * 2000-07-05 2011-06-14 pà de celulose, processo para produzir um pà de celulose, excipiente, e, produto moldado.
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US7842307B2 (en) * 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
WO2004004693A1 (en) * 2002-07-05 2004-01-15 Collgegium Pharmaceutical Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US20040208936A1 (en) * 2002-07-22 2004-10-21 Roland Chorin Novel compositions
EP2218448B1 (de) * 2002-12-13 2015-09-23 Durect Corporation Orale Darreichungsform mit flüssigen hochviskose Trägersystemen
US8906413B2 (en) * 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
DE10336400A1 (de) * 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
PT1842533E (pt) * 2003-08-06 2013-05-17 Gruenenthal Gmbh Forma de dosagem protegida contra abuso

Also Published As

Publication number Publication date
WO2006056713A1 (fr) 2006-06-01
JP2008520635A (ja) 2008-06-19
FR2878158B1 (fr) 2009-01-16
FR2878158A1 (fr) 2006-05-26
CA2589169A1 (fr) 2006-06-01
EP1814524B1 (de) 2012-04-18
EP1814524A1 (de) 2007-08-08
US20080260844A1 (en) 2008-10-23
CN101094653A (zh) 2007-12-26

Similar Documents

Publication Publication Date Title
WO2006089843A3 (fr) Forme medicamenteuse orale microparticulaire anti-mesusage
DE602005023203D1 (de) Zur verhinderung von missbrauch entworfene, feste arzneimittelform zur oralen verabreichung
EA200600696A1 (ru) Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств
WO2005041925A3 (en) Compositions and dosage forms for enhanced absorption
FR2878158B1 (fr) Forme pharmaceutique orale, microparticulaire solide concue pour eviter le mesusage
ATE355103T1 (de) Coextrudierte sicherheits-dosierform mit einem wirkstoff und einem adversen mittel und herstellungsverfahren dafür
WO2006056711A3 (fr) Medicament oral a liberation modifiee d'au moins un principe actif sous forme multimicrocapsulaire
ATE423556T1 (de) Capsaicin-enthaltende missbrauchsichere pharmazeutische zusammensetzungen
WO2007103293A3 (en) Ethanol-resistant sustained release formulations
WO2004009015A3 (en) Combination therapy for the treatment of obesity
TW200630093A (en) Dose forms
EP1824442A4 (de) Pharmazeutische und therapeutische zusammensetzungen aus der garcinia-mangostana-l-pflanze
UA90858C2 (ru) Композиция с контролируемым высвобождением варденафила
WO2007126832A3 (en) Pharmaceutical compositions for prevention of overdose or abuse
CY1110495T1 (el) Χρηση ενος αγωνιστη υποδοχεα nmda για τη θεραπεια εμβοης που προκαλειται απο κοχλιακη διεγερτοτοξικοτητα
WO2007112274A3 (en) Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin
MY143795A (en) Tetrahydropyridoindole derivatives
BRPI0513455A (pt) formulação para mascaramento de sabor compreendendo o fármaco em uma forma de dissolução retardada e/ou ciclodextrina em uma forma de dissolução melhorada
CY1107906T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει παραγωγα οιστετρολης για χρηση στην θεραπεια κατα του καρκινου
WO2006036770A3 (en) Combination therapy for the treatment of obesity
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
TW200800931A (en) Novel piperazines as antimalarial agents
TW200734334A (en) Treatment of substance abuse
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
JP2011500589A5 (de)